For decades, topical psoriasis treatment meant steroids and vitamin D creams, both with real limits on how long you could use them.
Zoryve and Vtama are two newer non-steroid options approved for plaque psoriasis, both once daily, both usable indefinitely, and both usable in the awkward places — face, skin folds, groin — where steroids cause the most trouble.
They work through completely different mechanisms, and the differences show up in side effects more than in results.
Both sit on the inflammation row without the collateral damage steroids cause — that is the entire reason they exist, and it shows as clean barrier and pigment rows for both. The mechanisms differ underneath: Zoryve blocks the PDE4 enzyme that amplifies inflammatory signals, while Vtama activates a receptor that both damps inflammation and helps restore the skin's own barrier proteins. Vtama's one cost shows on the pore row, as folliculitis.
Plaque psoriasis | Roughly equal | Moderate
Both were approved on solid vehicle-controlled trials. There is no good head-to-head comparison, so anyone claiming one is clearly better is going beyond the evidence.
Skin folds, groin, and face | Either | Strong
This is the shared advantage. Steroids are risky in these areas; both of these are safe there long-term.
Cosmetic feel | Zoryve | Moderate
It is a genuinely elegant cream that absorbs cleanly. Adherence to a daily topical depends heavily on whether people mind applying it.
Lasting effect after stopping | Vtama | Moderate
Its trials showed a notable stretch of remission after treatment ended, which is unusual for a topical.
Side effect profile | Zoryve | Moderate
Vtama commonly causes folliculitis — small bumps around hair follicles — which is not dangerous but bothers people. Zoryve's main issues are application-site irritation and, occasionally, headache or diarrhea.
Eczema as well as psoriasis | Either | Moderate
Both now have eczema indications, so if you have both conditions either can cover them.
Seborrheic dermatitis | Zoryve | Moderate
A specific foam formulation is approved for scalp and body seborrheic dermatitis, which is a distinct advantage.
Cost | Neither | —
Both are brand-only and expensive. Coverage is the deciding factor for most people, and it varies unpredictably by plan.
Skin of color | Either | Consensus
Neither lightens or thins skin, which makes both better long-term options than steroids on deeper tones — particularly on the face, where steroid-related pale patches are hard to hide.
Pick one. There is no reason to use both, and no evidence for combining them.
Choose Zoryve if: cosmetic feel matters to you, you also have seborrheic dermatitis, or you want to avoid the folliculitis risk.
Choose Vtama if: you want the best shot at a stretch of remission after stopping, or Zoryve has not worked well enough.
Let coverage decide if clinically it is a coin flip — which it often is. Ask your prescriber to check both before you leave, and ask about manufacturer savings programs. These are expensive drugs and the price difference between covered and uncovered is enormous.
Both still work alongside other treatments. People with more extensive psoriasis often use one of these on delicate areas and something else — a steroid, phototherapy, or a systemic drug — for the rest.
Give either 8 weeks. Both build gradually, and abandoning at week 3 is the most common mistake.
Moisturizer underneath, always. Neither replaces basic skin care.